Movexx-SP

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Movexx-SP

Quick Facts	Description
Active Ingredients	Aceclofenac, Paracetamol, Serrapeptase
Form	Fixed-Dose Combination (FDC) Tablet
Pharmacological Class	Analgesic, NSAID, and Systemic Enzyme Combination
General Purpose	Management of Pain, Inflammation, and Edema
Origin	Synthetic (Aceclofenac, Paracetamol) and Biological (Serrapeptase)

What Type of Medicine is Movexx-SP and What is its Composition?

Movexx-SP is a Fixed-Dose Combination (FDC) medicinal product, typically supplied as an oral tablet, and categorized as a combination Analgesic, Anti-inflammatory, and Systemic Enzyme agent. This tri-component formulation contains three active ingredients: Aceclofenac, Paracetamol (Acetaminophen), and Serrapeptase. Aceclofenac is a synthetic derivative belonging to the Non-Steroidal Anti-inflammatory Drug (NSAID) class, which works by inhibiting prostaglandin synthesis. Paracetamol, also synthetic, serves as an analgesic and antipyretic. The third component, Serrapeptase (Serratiopeptidase), is a biological/enzymatic substance used for its anti-inflammatory effects through its proteolytic activity. Aceclofenac with Paracetamol combinations are recognized in pharmacological practice for providing robust, dual-action pain relief.

How Does the Combination Approach Determine its General Purpose?

The general purpose of Movexx-SP is to achieve a synergistic therapeutic effect for the comprehensive management of combined pain, inflammation, and associated edema (swelling). The formulation is recognized for its layered approach to acute discomfort, such as that following mild musculoskeletal injury. The combination of an NSAID and an analgesic is a recognized strategy in pain therapy. The combination of an NSAID and Paracetamol is used to provide more effective pain relief than either drug alone.

While Aceclofenac and Paracetamol mitigate the chemical signals of inflammation and elevate the pain threshold, the inclusion of Serrapeptase introduces a unique differentiator. Proteolytic enzymes like Serrapeptase can help reduce swelling and inflammation by aiding in the breakdown and subsequent clearance of inflammatory byproducts. The enzyme component is intended to assist the body in clearing inflammation and swelling. This comprehensive strategy ensures the medicine simultaneously targets the source of inflammation, the perception of pain, and the physical manifestation of swelling.

What side effects are possible with Movexx-SP?

Possible side effects and safety information

This section summarizes the officially documented adverse reactions and safety restrictions for Movexx-SP, based strictly on government regulatory documents.

Adverse Reactions by Frequency and System

Adverse reactions are classified by how often they may occur and the body systems they affect:

Common (may affect up to 1 in 10 people): Reactions affecting the Gastrointestinal system (e.g., nausea, diarrhea, abdominal pain, indigestion) and Nervous system (e.g., dizziness, drowsiness). Increases in liver enzymes have also been noted.
Rare (may affect up to 1 in 1,000 people): Includes more serious events such as gastrointestinal bleeding or ulceration, hypersensitivity reactions, and visual disturbances.
Very Rare (may affect up to 1 in 10,000 people): This category includes severe skin reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), severe allergic reactions (anaphylactic shock), and kidney failure.

Serious Adverse Reactions and Safety Restrictions

Serious Adverse Reactions documented in regulatory sources include potentially fatal gastrointestinal bleeding or perforation, severe liver damage or failure, acute kidney failure, and an increased risk of arterial thrombotic events (e.g., heart attack or stroke) associated with the NSAID component.

Safety Restrictions and Contraindications: The medicine is generally not recommended during the third trimester of pregnancy or breastfeeding. It is contraindicated (should not be used) in patients with severe heart failure, active gastrointestinal ulcers or bleeding, or severe liver/kidney disease. Caution is required for elderly patients and those with existing cardiovascular risk factors (e.g., high blood pressure, diabetes) due to a higher risk of serious outcomes. The risk of serious complications, particularly stomach bleeding and kidney problems, is highlighted as increasing with higher doses and longer duration of treatment.

Overdose and Emergency Response

The official regulatory documents for medicines containing the active ingredients of Movexx-SP define the overdose profile by the risk of severe, delayed organ damage. Overdose manifestations may initially be non-specific, including nausea, vomiting, abdominal pain, pallor, and drowsiness. The most severe documented outcome is hepatic necrosis leading to liver failure from the Paracetamol component, which can be life-threatening and may not present with obvious signs until 12 to 48 hours after ingestion.

Regulators mandate that patients must seek immediate medical attention and contact emergency services without delay, even if symptoms are mild or absent. This urgent action is required because prompt management is essential to mitigate the risk of severe outcomes, such as acute renal failure or CNS effects like seizures and coma.

Specific management described in official labeling involves the use of the specific antidote N-acetylcysteine for Paracetamol toxicity, which must be administered as soon as possible. Procedures such as considering activated charcoal or gastric lavage may be necessary within one hour of ingestion to reduce absorption. Following intervention, continuous monitoring of hepatic and renal function is a documented requirement. No specific antidote is known for the Aceclofenac component.

Therapeutic Uses of Movexx-SP

Movexx-SP is a combination medicine that supports symptomatic relief in situations where symptoms related to physical discomfort, inflammation, and associated swelling (edema) appear together. The medication is commonly used to address multiple, co-occurring symptoms, providing supportive assistance in various acute and chronic contexts.

In pharmacological practice, the combination is utilized for the management of symptoms associated with conditions such as low back pain, cervical pain, spondylitis, osteoarthritis, and rheumatoid arthritis.

The medicine is commonly applied to help manage symptoms associated with chronic inflammatory musculoskeletal disorders, soft tissue injuries (like sprains and strains), post-operative discomfort, and acute aches such as menstrual cramps and tension-type headaches. It is used to help address symptom clusters by easing acute localized pain, supporting the management of physical swelling, and offering symptomatic relief when symptoms include fever.

“A primary goal of this therapeutic approach is to provide supportive relief during periods of heightened discomfort, helping to manage symptom fluctuations.”

This dual-action approach contributes to easing the overall symptom load and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Pain, Inflammation, and Swelling
Symptom Profile	Symptoms related to physical discomfort, inflammation, and localized swelling.
Common Scenarios	Used in settings involving post-traumatic swelling, chronic joint stiffness, and acute pain-fever episodes.
Key Benefit	Supports symptomatic relief that assists with maintaining functional stability.

Regulatory References

Rwanda FDA Product Information for ACEFORCE SP

Eligibility and Restrictions for Use

Who Can and Cannot Use Movexx-SP?

The official eligibility profile for Movexx-SP is defined by regulatory documents, which establish absolute contraindications and specific population restrictions.

Who Must Not Use Movexx-SP (Contraindications)

Movexx-SP is strictly contraindicated for populations with pre-existing conditions that pose significant risk, primarily due to the NSAID and Paracetamol components. Use is prohibited in patients with documented hypersensitivity to any component or other NSAIDs, active or recurrent peptic ulcers/GI bleeding, and severe impairment of hepatic (liver), renal (kidney), or cardiac (heart) function. Individuals with active bleeding or coagulation disorders must also avoid this medicine.

Age and Physiological Restrictions

Population Group	Regulatory Status
Pediatric (Under 18)	Use is not recommended; safety and efficacy are not established.
Older Adults (65+)	Requires special consideration due to increased risk of adverse reactions.
Pregnancy	Contraindicated during the third trimester and not recommended during the first two trimesters.
Lactation	Not recommended.

Conditional Use

Use requires caution and conditional assessment for patients with mild-to-moderate organ impairment, a history of gastrointestinal disorders, or cardiovascular risk factors like uncontrolled hypertension.

What should I know about interactions with other medicines?

Movexx-SP's interaction profile is governed by the specific regulatory constraints associated with its three active components. Formal restrictions strictly prohibit co-administration with other non-steroidal anti-inflammatory drugs (NSAIDs) or with any other medicinal product containing Acetaminophen.

A significant interaction profile involves Pharmacodynamic reinforcement affecting hemostasis. The combination requires careful consideration when co-administered with Anticoagulants (such as Warfarin) and antiplatelet agents, as this combination is documented to increase the risk of bleeding or haemorrhage. The interaction with Diuretics or specific Antihypertensives may result in a documented reduced efficacy of the blood pressure-lowering effect.

The profile also details specific Pharmacokinetic interactions. Co-administration with Lithium or Methotrexate is officially documented to decrease the renal elimination of these agents, resulting in elevated plasma concentrations. Furthermore, the label notes that interaction with Methotrexate requires caution if the two medicines are administered within a 24-hour period.

The Paracetamol component contributes to a metabolic risk profile: Hepatic enzyme inducers (such as Phenytoin) and chronic alcohol ingestion are officially noted as factors that increase the potential for hepatotoxicity.

Mechanism of Action

The overall effect of Movexx-SP is achieved through three complementary mechanistic domains that target distinct physiological pathways.

️ Modulation of Inflammatory Mediator Production

This domain covers Aceclofenac's action as an enzyme inhibitor, specifically targeting Cyclooxygenase-2 (COX-2). By disrupting the Arachidonic Acid Cascade, the mechanism suppresses the synthesis of pro-inflammatory prostaglandins at the injury site, thereby limiting peripheral chemical signaling that results in a diminished inflammatory reaction.

Central Regulation of Pain Perception

This effect is primarily driven by Paracetamol's action within the Central Nervous System (CNS). The mechanism involves inhibiting prostaglandin synthesis centrally and modulating descending serotonergic pathways that control pain transmission. This action elevates the body's internal pain threshold and initiates heat dissipation from the hypothalamus.

Enzymatic Resolution of Local Swelling

This unique domain features the proteolytic enzyme Serrapeptase, which acts systemically. Its mechanism involves the hydrolysis (breakdown) of protein substrates like fibrin and kinins found in inflammatory exudates (fluid accumulation). This action lowers the viscosity of the fluid and facilitates its reabsorption into the body's circulation, thereby improving the reabsorption of fluid from the extravascular space.

Dosage and Administration Information

How to Use Movexx-SP

Movexx-SP is a Fixed-Dose Combination (FDC) medicinal product designated for oral administration as a film-coated tablet. Standard administration parameters are established regarding dose, frequency, and conditions of intake.

Standard Regimen and Frequency

The standard reported regimen for adults is one tablet of the 100 mg Aceclofenac / 325 mg Paracetamol / 15 mg Serratiopeptidase strength. The regimen involves taking the tablet twice daily, once in the morning and once in the evening, to achieve the intended effect. The maximum recommended intake is limited to two tablets daily.

Usage is generally governed by the principle of administering the lowest effective dose for the shortest duration necessary for symptomatic control. The medicine is commonly utilized for short-term courses to address acute inflammatory or painful episodes.

Administration Conditions and Restrictions

Condition	Official Instruction
Tablet Integrity	The tablet is intended to be swallowed whole with sufficient liquid. It is not to be crushed, chewed, or broken.
Timing with Food	The tablet is typically taken preferably with or immediately after food.
Critical Restriction	Usage guidelines specify the product is not to be taken concomitantly with any other medicines containing Paracetamol (acetaminophen).

Population-Specific Considerations

Formal dose adjustments are noted for specific clinical scenarios. For patients with hepatic impairment, a dose reduction is suggested, typically to one tablet once daily (based on the Aceclofenac component's guideline of 100 mg per day). Use of this FDC tablet is not recommended in the pediatric population due to a lack of supporting clinical data.

Recent Clinical Evidence

Research evidence / Overview of studies for Movexx-SP

The research landscape for the Movexx-SP combination, which includes Aceclofenac, Paracetamol, and Serrapeptase, includes studies that explored symptom patterns over defined intervals in certain painful and inflammatory conditions. Research examined data related to outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Evidence for Acute Pain and Swelling After Procedures

This section summarizes the types of short-term, comparative studies and Randomized Controlled Trials (RCTs) that have explored the combination relevant to pain and associated swelling following procedures like dental surgery. Clinical research explored adult patients undergoing minor procedures, such as dental implant placement or extractions. Studies monitored outcomes related to physical discomfort and the extent of swelling (edema) during the initial acute phase.

Research describes the measurements recorded during the study period for both pain intensity and localized swelling. Studies report mixed findings when the Serrapeptase component was compared to the established two-drug pain relief combination. Additionally, the existing evidence provides limited insight into outcomes beyond the initial days of recovery, as follow-up durations were limited.

Evidence for Acute Flare-ups in Musculoskeletal Conditions

This part details the structure of the clinical trials that focused on the triple combination's use in contexts involving acute symptom exacerbations related to inflammatory disorders such as Osteoarthritis and other regulator-cited musculoskeletal conditions (e.g., low back pain). Research was studied for conditions characterized by fluctuating or episodic manifestations.

Findings describe patterns observed in the studies regarding pain and functional assessments over short treatment periods. Evidence derived from these settings contributes to the broader evidence landscape for short-term symptom relief. Limited information for long-term outcomes exists for the specific triple formulation, and much supporting data is focused on the established efficacy of the dual NSAID and Paracetamol combination.

What Research Remains Uncertain or Limited

Overall, the evidence is limited to the short-term symptomatic use of the combination, meaning the results apply only to the populations studied and the brief durations monitored. Scientific reviews consistently cite the need for more extensive, methodologically rigorous, and longer-duration studies, particularly to fully characterize the long-term profile and the consistent added contribution of the Serrapeptase component. This research contributes to understanding what has been studied — and what remains uncertain.

Key Studies & References

How should Movexx-SP be stored and disposed of?

Movexx-SP must be stored strictly according to regulatory labeling to maintain the stability and efficacy of its fixed-dose combination.

Required Storage and Handling

Temperature: Store the tablets at controlled room temperature, not exceeding 30 C (86 F). Environments above this limit are prohibited.
Protection: The medicine must be kept in a cool, dry place and protected from light and moisture to preserve the 24-month shelf life.
Packaging: Keep the tablets in their original blister pack/container until the time of use.
Child Safety: It is mandatory to keep Movexx-SP out of the sight and reach of children.

Official Disposal Rules

Disposal instructions state that there are no special precautions for disposal (non-hazardous waste). Unused or expired tablets must be discarded according to local regulations, preferably through a community drug take-back program. If a program is unavailable, follow governmental guidelines for disposal in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z